<DOC>
	<DOCNO>NCT00103610</DOCNO>
	<brief_summary>The purpose study determine whether combination AMD3100 ( plerixafor ) granulocyte colony-stimulating factor ( G-CSF generic name filgrastim ) good G-CSF alone mobilize collect optimal number stem cell non-Hodgkin 's lymphoma patient autologous transplantation .</brief_summary>
	<brief_title>Mobilization Stem Cells With AMD3100 ( Plerixafor ) Non-Hodgkin 's Lymphoma Patients</brief_title>
	<detailed_description>A peripheral stem cell transplant may able replace blood-forming cell destroy chemotherapy . Currently filgrastim ( G-CSF ) , colony stimulate factor , use cause growth mobilization stem cell bone marrow peripheral blood , collect peripheral blood process call apheresis . Plerixafor aids release stem cell bone marrow peripheral blood , possibly allow rapid collection large number stem cell peripheral blood . Larger stem cell dose transplantation correlate faster recovery times high dose chemotherapy follow stem cell transplantation . This study intend determine whether combination plerixafor filgrastim well filgrastim alone help non-Hodgkin 's lymphoma patient collect least 5 million stem cell four less apheresis session . This study previously post AnorMED , Inc . In November 2006 , AnorMED , Inc. acquire Genzyme Corporation . Genzyme Corporation sponsor trial .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Inclusion Criteria ( Abbreviated List ) : NonHodgkin 's lymphoma first second complete partial remission Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 White Blood Cell count ( WBC ) &gt; 2.5*10^9/L Platelet ( PLT ) &gt; 100*10^9/L Exclusion Criteria ( Abbreviated List ) : Failed previous stem cell collection Prior autologous allogeneic transplant Brain metastases bone marrow involvement &gt; 20 % Radiation pelvis Abnormal electrocardiogram ( ECG ) rhythm disturbance ( ventricular arrhythmia ) conduction abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Non-Hodgkin 's lymphoma</keyword>
	<keyword>Stem cell mobilization</keyword>
</DOC>